SCHEDULE: Millennium Entities Report Stake in ARS Pharmaceuticals

Several entities affiliated with Millennium Management have jointly filed a Schedule 13G, reporting beneficial ownership of ARS Pharmaceuticals common stock.

Summary

• Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G.
• The filing pertains to their beneficial ownership of ARS Pharmaceuticals, Inc. common stock.
• The reporting date for this event is June 30, 2026.
• Integrated Core Strategies (US) LLC reports shared voting and dispositive power over 1,336,609 shares, representing 1.3% of the class.
• Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander each report shared voting and dispositive power over 2,520,937 shares, representing 2.5% of the class.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a routine disclosure of beneficial ownership by investment entities and does not provide new operational or financial performance information.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding future performance.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment management firms to report significant stakes in publicly traded companies. The joint filing by entities associated with Millennium Management indicates a coordinated investment strategy.

Key Dates

Keywords

ARS Pharmaceuticals, Schedule 13G, Millennium Management, Integrated Core Strategies, Beneficial Ownership, SEC Filing, Common Stock, Investment